Biotricity, Inc. (BTCY)
NASDAQ: BTCY · IEX Real-Time Price · USD
0.851
-0.009 (-1.05%)
At close: Nov 28, 2023, 3:11 PM
0.850
-0.001 (-0.13%)
After-hours: Nov 28, 2023, 5:54 PM EST
Company Description
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States.
The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.
It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components.
The company is based in Redwood City, California.
Biotricity, Inc.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Dr. Waqaas Al-Siddiq Ph.D. |
Contact Details
Address: 203 Redwood Parkway, Suite 600 Redwood City, California 94065 United States | |
| Phone | (650) 832-1626 |
| Website | biotricity.com |
Stock Details
| Ticker Symbol | BTCY |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001630113 |
| CUSIP Number | 09074H104 |
| ISIN Number | US09074H1041 |
| Employer ID | 47-2548273 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Waqaas Al-Siddiq Ph.D. | Founder, President, Chief Executive Officer and Chairman |
| S. John Ayanoglou | Chief Financial Officer |
| Dr. George N. Nikopoulos | Director of Business Development |
| Amir Ali | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 6, 2023 | 8-K | Current Report |
| Sep 20, 2023 | 8-K | Current Report |
| Sep 19, 2023 | 424B5 | Filing |
| Aug 17, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Aug 4, 2023 | 8-K | Current Report |
| Jul 21, 2023 | 424B3 | Prospectus |
| Jul 20, 2023 | 8-K | Current Report |
| Jul 5, 2023 | 8-K | Current Report |